866-997-4948(US-Canada Toll Free)

Published on : Nov 04, 2015

Hutchison China MediTech Ltd., also called Chi-Med, rose 1.37% during the trading session on Nov 02, 2015. The stock hit GBX 2582.50 whereas 27,815 shares changed hand during trading hours.

The market cap of this stock is GBX 1.38 bn and the 50 day average moving price of the company is GBX 2,094.19. The 200 day average moving price of Chi-Med is GBX 1,869.83. The stock has a 52-week high of GBX 2,860 and a 52-week low of GBX 1,140.

The stock of Hutchison China MediTech Ltd. has been reaffirmed a ‘buy’ rating by Beaufort Securities reaffirmed. The financial firm released a research note on Monday stating the same. In a separate note released on July 28th, 2015, Panmure Gordon reiterate a ‘buy’ rating on the stock and put a target price of US$27 per share.

The company is Hong Kong-based and functions into the pharma and the medical and healthcare industry. The firm is engaged in researching, developing, producing, and marketing pharmaceuticals and health-related products.

Basically the firm operates in three business segments, namely drug research and development, China healthcare, and consumer products. The China healthcare segment is involved into the development, production, marketing, supply, and sale of prescription drugs, over-the-counter products, and health supplements products, whereas drug research and development segment is involved in drug discoveries and other R&D activities related to pharma. The consumer products segment operates the sale of health-related products.

Mr. Christopher Nash, an independent director at Hutchison China MediTech Ltd. has bought around 4,512 shares of the company on Oct 20th, 2015. The total price paid by Mr. Nash for this procurement was US$1.53 mn that amounted to US$33.87 per share